Previous 10 | Next 10 |
NEWARK, CA / ACCESSWIRE / April 4, 2023 / Protagonist Therapeutics (NASDAQ:PTGX) ("Protagonist" or the "Company") today announced the pricing of its previously announced underwritten public offering of 5,000,000 shares of its common stock at a public offering price of $20.00 per share. Gross pro...
2023-04-04 16:43:24 ET Protagonist Therapeutics ( NASDAQ: PTGX ) is trading ~3% lower after an underwritten public offering of $100M of common stock. Protagonist expects to grant the underwriters a 30-day option to purchase up to an additional $15M of shares at the public ...
NEWARK, CA / ACCESSWIRE / April 4, 2023 / Protagonist Therapeutics (NASDAQ:PTGX) ("Protagonist" or the "Company") today announced that it has commenced an underwritten public offering of $100 million of shares of its common stock. All of the securities to be sold in the offering are being offere...
2023-03-17 16:16:22 ET Summary Here's a long list of biopharmas exposed to SVB Financial Group. Many of these deposits will be uninsured. However, since SVB Financial Group was quite solvent otherwise, much of these deposits should be recoverable by these small companies. ...
2023-03-15 16:46:54 ET Protagonist press release ( NASDAQ: PTGX ): Q4 GAAP EPS of -$0.69 misses by $0.10 . Cash, cash equivalents and marketable securities as of December 31, 2022 were $237.4 million. R&D expenses for the fourth quarter and full year 2022 were ...
Positive results from the Phase 2b FRONTIER 1 study of JNJ-2113 (formerly PN-235) in moderate-to-severe psoriasis, paving a path forward for initiation of a Phase 3 pivotal study Highly statistically significant results from the randomized withdrawal portion of the REVIVE study of rusfertide...
2023-03-10 21:26:19 ET Several smaller pharma and biotech companies have come out and said they have exposure to FDIC-shuttered Silicon Valley Bank ( SIVB ). The biotech was the biggest exposure disclosed so far is Sangamo Therapeutics ( NASDAQ: SGMO ), with $34.4M in ...
2023-03-09 08:15:00 ET Summary With back-to-back clinical data readouts of Protagonist Therapeutics' lead product candidates this month, the first one led to a 50% run. This agent being picked for Phase 3 development on the strength of these statistically significant but mysteriou...
2023-03-07 13:40:42 ET While a negative response to comments from Federal Reserve Chair Jerome Powell drove trading in Tuesday's midday trading, earnings news remained a mover for certain individual stocks. This included BlackBerry ( NYSE: BB ), which slumped after releasing prelimi...
2023-03-07 12:39:41 ET Gainers: ThredUp ( TDUP ) +73% . WW International ( WW ) +49% . Unicycive ( UNCY ) +39% . Protagonist Therapeutics ( PTGX ) +32% . Bionomics ( BNOX ) +28% . Novo Integrated Sciences ( NVOS ) +25% ...
News, Short Squeeze, Breakout and More Instantly...
Protagonist Therapeutics Inc. Company Name:
PTGX Stock Symbol:
NASDAQ Market:
Protagonist Therapeutics Inc. Website:
NEWARK, CA / ACCESSWIRE / August 1, 2024 / Protagonist Therapeutics, Inc. ("Protagonist" or the "Company") today announced publication of preclinical and phase 1 clinical data on JNJ-2113 in the journal Scientific Reports , a Nature publication and the 5th most-cited journal in the world, acc...
NEWARK, CA / ACCESSWIRE / August 1, 2024 / Protagonist Therapeutics, Inc. ("Protagonist" or the "Company") today announced publication of preclinical and phase 1 clinical data on JNJ-2113 in the journal Scientific Reports , a Nature publication and the 5th most-cited journal in the world, acc...
Dr. Yeilding joins Protagonist from Janssen Pharmaceutical Companies of Johnson & Johnson, where he held leadership roles in the immunology therapeutic area, bringing extensive experience in R&D and commercialization of novel therapeutics in the I&I space NEWARK, CA / ACCESSWIRE /...